Eli Lilly

Showing 15 posts of 198 posts found.

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

August 23, 2023
Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …


Eli Lilly shares data from two phase 3 tirzepatide studies

July 28, 2023
Research and Development Eli Lilly, Obesity, clinical trial, tirzepatide, weight loss

Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients with obesity or who are …


Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment

July 18, 2023
Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab

Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …

Eli Lilly to acquire Versanis Bio for $1.9bn

July 17, 2023
Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …


Eli Lilly to acquire Sigilon Therapeutics

June 30, 2023
Business Services Chronic Diseases, Eli Lilly, Sigilon, acquisition

Eli Lilly and Sigilon Therapeutics have announced a definitive agreement for Lilly’s acquisition of Sigilon, a biopharmaceutical company focusing on …

Eli Lilly to acquire DICE Therapeutics for immunology innovations

June 21, 2023
Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology

Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

May 5, 2023
Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023
Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …


Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

June 28, 2021
Sales and Marketing Eli Lilly, semaglutide, type 2 diabetes

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C and body weight reductions compared …

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

June 25, 2021
Medical Communications Alzheimer's, Eli Lilly, FDA

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing plans on Thursday to file …

NICE recommends two new treatments for inflammatory arthritis

June 18, 2021
Medical Communications Eli Lilly, NICE, Novartis

NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …

Eli Lilly and MiNA Therapeutics to collaborate on saRNA research

May 12, 2021
Research and Development Eli Lilly

Eli Lilly and MiNA Therapeutics have announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small …


Eli Lilly to collaborate with diabetes tech companies on insulin pen

May 10, 2021
Sales and Marketing Eli Lilly, diabetes

Eli Lilly has signed strategic international agreements with four companies – Dexcom, Glooko, myDiabby Healthcare, and Roche – with the …

Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

April 19, 2021
Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …

Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

March 17, 2021
Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …

Latest content